Intestinal Microbiota Transplantation for Treating Advanced Tumor Cachexia
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorHua Jiang
About this trial
This project is a prospective, multicenter, single-arm, phase II clinical study aimed at evaluating the efficacy and safety of fecal microbiota transplantation (FMT) in treating advanced tumor cachexia.
Eligibility criteria
Qualifiers
Pre-advanced or advanced tumor cachexia stage.
Age ≥ 18 years old, ECOG score 0-2, expected survival > 3 months.
Patients with gastric cancer, colorectal cancer, or lung cancer who have received second-line or higher treatment.
No FMT treatment in the past six months.
Disqualifiers
Any condition that affects gastrointestinal absorption, such as difficulty in swallowing, malabsorption, or uncontrollable vomiting; undergoing tube feeding or parenteral nutrition.
Neurotic anorexia, anorexia caused by mental illness, or difficulty in eating due to pain.
Acquired immunodeficiency syndrome.
Currently taking or planning to take other drugs that increase appetite or weight, such as adrenal corticosteroids (except for short-term use of dexamethasone during chemotherapy), androgens, progestogens, salidroside, olanzapine, and anamorin or other appetite stimulants.
Trial design
Treatments tested in this trial
- FMT capsule
Treatment groups
66 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Hua Jiang
Lead sponsor
Changzhou No.2 People's Hospital
Sponsor institution
Source ClinicalTrials.gov